GoAI
Get started
Jade Biosciences, Inc. logo

Jade Biosciences, Inc.

JBIO

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$21.34

+$0.11 · +0.52%

Aug 21, 4:00 PM ET

JBIO company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

37

Expensive

Momentum

67

Gaining

Sentiment

66

Bullish

Risk resilience

43

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Jade Biosciences, Inc. operates as a biotechnology enterprise, primarily focused on pioneering superior therapeutic solutions for significant unmet medical requirements in autoimmune disorders. Its leading development candidate, JADE-001, specifically targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway, aiming to treat immunoglobulin A (IgA) nephropathy. Clinical trials for JADE-001 are slated to commence in the latter half of 2025, with initial results projected for the first half of 2026. Beyond this lead asset, the company's robust pipeline includes two preclinical antibody programs, JADE-002 and JADE-003.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Tom Frohlich
Listed since
Jun 30, 2021
Employees
55

Market position

Day range

Current $21.34

52-week range

Current $21.34

Open
$21.45
Previous close
$21.23
Volume
571.85K
0.59× average
Average volume
971.81K
Average daily volume
Market cap
1.3B USD
Beta
1.49
Market reference 1
50-day average
$20.798
+2.61% above average
200-day average
$17.456
+22.25% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
396.17M USD
EV / EBITDA
-3.11×
Earnings yield
-26.33%
Free cash flow yield
-19.61%

Profitability & efficiency

Return on equity
-38.32%
Return on assets
-36.43%
Return on invested capital
-34.07%

Financial health

Current ratio
20.33×

Financial statements

Income trends

Operating income

−113.54M USD-52.21%

Net income

−127.41M USD-82.99%
Income trends across reported periods−12.52M USD−54.3M USD−96.08M USD−137.85M USDOperating income, FY2021: −23.02M USDOperating income, FY2022: −53.24M USDOperating income, FY2023: −81.41M USDOperating income, FY2024: −74.6M USDOperating income, FY2025: −113.54M USDNet income, FY2021: −22.96M USDNet income, FY2022: −51.51M USDNet income, FY2023: −75.52M USDNet income, FY2024: −69.63M USDNet income, FY2025: −127.41M USDFY2021FY2022FY2023FY2024FY2025
Operating income FY2021 −23.02M USD. Operating income FY2022 −53.24M USD. Operating income FY2023 −81.41M USD. Operating income FY2024 −74.6M USD. Operating income FY2025 −113.54M USD. Net income FY2021 −22.96M USD. Net income FY2022 −51.51M USD. Net income FY2023 −75.52M USD. Net income FY2024 −69.63M USD. Net income FY2025 −127.41M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Cost of goods sold—282K USD96K USD68K USD15K USD
Gross profit—−282K USD−96K USD−68K USD−15K USD
Research and development93.12M USD53.19M USD64.22M USD38.62M USD14.99M USD
Selling, general, and administrative20.42M USD21.13M USD17.09M USD14.55M USD8.02M USD
Operating expenses113.54M USD74.31M USD81.31M USD53.17M USD23.01M USD
Interest income7.78M USD5.04M USD5.95M USD1.83M USD65K USD
Depreciation and amortization26K USD282K USD96K USD68K USD15K USD
Operating income−113.54M USD−74.6M USD−81.41M USD−53.24M USD−23.02M USD
Net income−127.41M USD−69.63M USD−75.52M USD−51.51M USD−22.96M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
9%
1 beat, 9 misses, 1 met estimate
Average EPS surprise
-23.38%
11 comparable reports
Latest EPS result
-0.76
Estimate -0.64 · Miss by 19.42%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.37-4.59-8.81-13.03Q1 '25MissQ2 '25MissQ3 '25MissQ4 '25BeatQ1 '26MetQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 14, 2025: actual -6.65, estimate -6.57, surprise -1.17%, Miss. Q2 2025, reported Apr 25, 2025: actual -12.1, estimate -6.03, surprise -100.83%, Miss. Q3 2025, reported Aug 14, 2025: actual -0.86, estimate -0.43, surprise -100.00%, Miss. Q4 2025, reported Nov 14, 2025: actual -0.48, estimate -0.57, surprise +15.79%, Beat. Q1 2026, reported Mar 6, 2026: actual -0.45, estimate -0.45, surprise 0.00%, Met estimate. Q2 2026, reported May 7, 2026: actual -0.57, estimate -0.52, surprise -9.62%, Miss. Q3 2026, reported Aug 10, 2026: actual -0.76, estimate -0.636, surprise -19.42%, Miss. Q4 2026, reported Nov 12, 2026: actual —, estimate -0.73, surprise —, Comparison unavailable.

JBIO peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding JBIO

Funds reporting this stock among their holdings, ordered by reported position size.

State Street SPDR S&P Biotech ETF logoState Street SPDR S&P Biotech ETFXBI
Market value
34.18M
Weight
0.30%
AUM
11.39B USD
Expense ratio
0.35%
Price / 1D
$165.73+1.44%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
33.56M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
17.81M
Weight
0.02%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
9.68M
Weight
0.01%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
6.35M
Weight
0.04%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
3.61M
Weight
0.02%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
Vanguard Health Care ETF logoVanguard Health Care ETFVHT
Market value
2.49M
Weight
0.01%
AUM
20.9B USD
Expense ratio
0.09%
Price / 1D
$327.7+1.24%
Vanguard U.S. Momentum Factor ETF logoVanguard U.S. Momentum Factor ETFVFMO
Market value
2.48M
Weight
0.12%
AUM
1.8B USD
Expense ratio
0.13%
Price / 1D
$232.52+0.68%

Continue in GoAI

Research JBIO

research.disclaimer